Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort

被引:16
作者
Deloria-Knoll, M
Chmiel, JS
Moorman, AC
Wood, KC
Holmberg, SD
Palella, FJ
机构
[1] Northwestern Univ, Div Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Atlanta, GA USA
[3] Cerner Corp, Vienna, VA USA
关键词
D O I
10.1089/apc.2004.18.721
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In a confidential medication adherence questionnaire completed by 255 participants in the HIV Outpatient Study (HOPS) between March and November 1999, 33% reported skipping antiretroviral doses within the previous 3 days. The respondents, with a median age of 41, were predominantly male (86%), white (62%), and highly educated (33% had some post-high school training but no college degree and 39% had a college degree; only 11% had less than a high school diploma). Twenty-one percent had a history of injection drug use, 12% were unemployed, and 18% had Medicaid insurance. Questions about difficulty taking antiretroviral medications or drug holidays identified an additional 16% of patients experiencing adherence problems and explained significantly more of the failure to achieve undetectable viral loads than simply querying about skipped doses.
引用
收藏
页码:721 / 727
页数:7
相关论文
共 12 条
[1]   High levels of adherence do not prevent accumulation of HIV drug resistance mutations [J].
Bangsberg, DR ;
Charlebois, ED ;
Grant, RM ;
Holodniy, M ;
Deeks, SG ;
Perry, S ;
Conroy, KN ;
Clark, R ;
Guzman, D ;
Zolopa, A ;
Moss, A .
AIDS, 2003, 17 (13) :1925-1932
[2]   Adherence to HAART regimens [J].
Chesney, M .
AIDS PATIENT CARE AND STDS, 2003, 17 (04) :169-177
[3]   The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials [J].
Mannheimer, S ;
Friedland, G ;
Matts, J ;
Child, C ;
Chesney, M .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) :1115-1121
[4]   Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic [J].
McNabb, J ;
Ross, JW ;
Abriola, K ;
Turley, C ;
Nightingale, CH ;
Nicolau, DP .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (05) :700-705
[5]   Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: The HIV outpatient study (HOPS) [J].
Moorman, AC ;
Holmberg, SD ;
Marlowe, SI ;
Von Bargen, JC ;
Yangco, BG ;
Palella, FJ ;
Ward, DJ ;
Loveless, MO ;
Fuhrer, J ;
Joseph, P ;
Alexander, W ;
Aschman, DJ .
ANNALS OF EPIDEMIOLOGY, 1999, 9 (06) :349-357
[6]   Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].
Palella, FJ ;
Delaney, KM ;
Moorman, AC ;
Loveless, MO ;
Fuhrer, J ;
Satten, GA ;
Aschman, DJ ;
Holmberg, SD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860
[7]   Adherence to protease inhibitor therapy and outcomes in patients with HIV infection [J].
Paterson, DL ;
Swindells, S ;
Mohr, J ;
Brester, M ;
Vergis, EN ;
Squier, C ;
Wagener, MM ;
Singh, N .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :21-30
[8]   Daily dosing of highly active antiretroviral therapy [J].
Rosenbach, KA ;
Allison, R ;
Nadler, JP .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :686-692
[9]   Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice [J].
Stone, VE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (06) :865-872
[10]   Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients [J].
Turner, BJ .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 :S143-S151